ENVERIC BIOSCI.INC.DL-,01 (SLZA.MU)
- Business Wire
Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373
CAMBRIDGE, Mass., March 23, 2023--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that it has entered into an agreement with Avance Clinical, an Australia-based contract research organization (CRO) with US operations, for its planned Phase 1 clinical trial of EB-373, the company’s lead candidate targeti
- Business Wire
Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications
CAMBRIDGE, Mass., March 21, 2023--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that it has established Enveric Therapeutics Pty. Ltd., an Australia-based subsidiary, to support the Company’s plans to advance its EVM201 Series, including lead candidate EB-373, towards the clinic. Enveric Therapeutics will o
- Business Wire
Enveric Biosciences Announces Bioproduction Platform Using Novel Cane Toad Enzyme for Psychedelic-Inspired Drug Discovery
CAMBRIDGE, Mass., March 14, 2023--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, announced today new research detailing the first-ever isolation of a novel indolethylamine N-methyltransferase from cane toad (Rhinella marina) and the successful development of a bioproduction platform for the isolation and pharmacological scr
